An interventional study of Saccharin and Sucralose in Prediabetic State, Metabolic Syndrome and Insulin Resistance, sponsored by Charite University, Berlin, Germany. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.
Artificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).
However, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.
After enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.
The investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
This study's planned enrollment of 80 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.
Browse Prediabetic State studies →Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Saccharin
Dietary Supplement: Saccharin
Intervention: Sucralose
Dietary Supplement: Sucralose
Intervention: Erythritol
Dietary Supplement: Erythritol
Intervention: Vehicle
Dietary Supplement: Vehicle
Participants in the saccharin group will consume 5 mg/kg body weight of saccharin daily, dissolved in 500 mL of water. This corresponds to the maximum recommended daily intake as determined by EFSA and JECFA (the joint FAO/WHO Expert Committee on Food Additives).
Participants in the sucralose group will consume 15 mg/kg body weight of sucralose daily in 500 mL of water, representing the maximum recommended daily intake.
Those in the erythritol group will consume 0.5 g/kg body weight of erythritol daily in 500 mL of water, a dose considered safe and below levels that cause digestive discomfort (European Food Safety Authority \[EFSA\], 2023).
Participants in the control group (vehicle) will receive a vehicle consisting of 500 mL unsweetened lemon soda
Change of glucose tolerance
Measured by AUC of oral glucose tolerance test
Time frame: Baseline vs. within 1 week after intervention
Change of microbiome
RNA-Sequencing of stool samples
Time frame: Baseline vs. within 1 week after intervention
Flow cytometry analysis of changes in frequency of circulating monocyte subsets (%)
Measured by flow cytometry in isolated PBMCs (Peripheral Blood Mononuclear Cells) using specific antibodies with binding to CD45, CD14, CD15 and CD16 to define monocyte subsets. Values will be reported as percent of CD45+ leukocytes
Time frame: Baseline vs. within 1 week after intervention
Flow cytometry analysis of changes in platelet activation marker expression (% positive platelets)
Whole blood samples will be analyzed using flow cytometry. Platelets will be detected based on size and using well-established surface markers (CD41). Activation markers will be assessed (CD62P and PAC1) and reported as percent of positive cells.
Time frame: Baseline vs. within 1 week after intervention
Flow cytometry analysis of changes in platelet activation marker expression (MFI)
Whole blood samples will be analyzed using flow cytometry. Platelets will be detected based on size and using well-established surface markers (CD41). Activation markers will be assessed (CD62P and PAC1) and reported as mean fluorescence intensity.
Time frame: Baseline vs. within 1 week after intervention
Changes in lipid profile
Serum analysis of Total cholesterol, HDL and LDL cholesterol, triglycerides
Time frame: Baseline vs. within 1 week after intervention
Changes in blood metabolite profiles by liquid chromatography / mass spectrometry
Untargeted metabolomics analysis of plasma samples using liquid chromatography-mass spectrometry (LC/MS). Data will be reported as relative ion intensity changes from baseline (log2 fold change, mean ± SD) for significantly altered features.
Time frame: Baseline vs. within 1 week after intervention
Changes in body mass index (BMI)
To observe changes in anthropometric measures. Measurement of height in meters and weight in kilograms to calculate body mass index (BMI = weight/height\^2) in kg/m\^2
Time frame: Baseline vs. within 1 week after intervention
Changes in waist to hip ratio (WHR)
To observe changes in anthropometric measures. Measurement of waist circumference and hip circumference to calculate waist-to-hip-ratio WHR (waist circumference divided by hip circumference).
Time frame: Baseline vs. within 1 week after intervention
Changes in body fat percentage
Measured by Bioelectrical Impedance Analysis (BIA)
Time frame: Baseline vs. within 1 week after intervention
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Jan 2026; primary completion for Nov 2026, 9 months later.
Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 9 months is below that.
Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saccharin · Trichlorosucrose · Erythritol
Charite University, Berlin, Germany →